

**N4 Pharma plc
("N4 Pharma" or the "Company")**

N4 Pharma CEO Q&A Now LIVE

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce the release of an investor Q&A from CEO, Nigel Theobald.

Investors were invited to submit questions on the [October 2024 New Corporate Presentation, full slide deck here](#).

The Q&A response is now live on N4 Pharma's interactive investor hub here: <https://investors.n4pharma.com/link/0y5jle>.

Any additional follow up questions from investors will be answered by CEO Nigel Theobald in the coming days via the hub.

For more information please contact:

N4 Pharma plc

Nigel Theobald, CEO
Luke Cairns, Executive Director

Via IFC Advisory

SP Angel CorporateFinance LLP

Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited

Joint Broker
Andy Thacker
James Pope

Tel: +44(0)20 3657 0050

IFC Advisory Ltd

Financial PR
Graham Herring
Zach Cohen

Tel: +44(0)20 3934 6630

InvestorHub

Engage with us directly at N4 Pharma Investor Hub

Sign up
at investors.n4pharma.com

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at <https://investors.n4pharma.com/auth/signup>.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEAXEFDFFFA